Previous clinical trials have demonstrated how TRIM21 reduces de novo lipogenesis and steatosis in hepatocytes by inhibiting FASN; this mechanism is detected in patients with TRIM21, which reduces hepatic de novo lipogenesis and steatosis in patients with obesity and MAFLD and obesity [67]. This evidence concerns the gene FASN and obesity due to melanocortin 4 receptor deficiency.